Review Article Insulin-like growth factor-1 receptor-targeted therapy for non-small cell lung cancer: a mini review
Ming Yin, Xiaoxiang Guan, Zhongxin Liao, Qingyi Wei
Departments of Epidemiology and Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
Received January 24, 2009; accepted January, 2009; available online January, 2009
Abstract: Lung cancer leads all other cancers in both incidence and mortality. Recent advances in underlying molecular pathogenesis have validated a panel of protein tyrosine kinases as new targets in lung cancer treatment. Insulin-like growth factor-1 receptor (IGF-1R) is an important tyrosine kinase receptor involved in cell proliferation, differentiation, metabolism, apoptosis, and angiogenesis. Aberrant activation of IGF-1R is frequently found in patients with lung cancer and contributes to malignant transformation and poor prognosis for patients with lung cancer. In this review, we focused on recent progress in the research of IGF-1R’s role in lung cancer development and progression, including its structure and biological function, potential mechanisms of aberrant activation, and related oncogenic effects. We also discussed effective IGF-1R antagonists that are currently registered for clinic trials or are undergoing preclinical study with special emphasis on their antibodies and small molecule tyrosine kinase inhibitors. (AJTR901008).
Address all correspondence to: Qingyi Wei, MD, PhD Department of Epidemiology The University of Texas, M. D. Anderson Cancer Center 1515 Holcombe Blvd, Unit 1365 Houston, TX 77030, USA Tel: 1 713 792 3020 Fax: 1 713 563 0999 E-mail: firstname.lastname@example.org